已上市乙脑疫苗免疫原性与安全性的系统评价与网状Meta分析
该研究系统检索四个数据库的随机对照试验,纳入23项研究共38496名参与者,比较四类乙脑疫苗的免疫原性与安全性。网状Meta分析显示,新型疫苗免疫原性均优于鼠脑灭活疫苗,其中活嵌合疫苗(OR=5.93;95%CI:1.73-20.32)和Vero细胞灭活疫苗(OR=2.98;95%CI:1.02-8.65)差异有统计学意义;鼠脑灭活疫苗不良事件风险最高(OR=2.27;95%CI:1.59-3.23),新型疫苗不良事件风险与安慰剂无差异,各类疫苗严重不良事件无差异。
要点
- 活嵌合与Vero细胞灭活乙脑疫苗免疫原性优于鼠脑灭活疫苗。
- 鼠脑灭活疫苗不良事件风险最高,新型疫苗与安慰剂无差异。
- 各类乙脑疫苗严重不良事件无差异。
核心结论
- 所有新型乙脑疫苗安全性相当,活嵌合和Vero细胞灭活疫苗在新型疫苗中免疫原性最强。
研究设计与样本
- 系统检索四个数据库的随机对照试验,纳入23项研究共38496名参与者。
- 疫苗分为四类:鼠脑灭活(最老类别)、Vero细胞灭活、活嵌合、减毒活疫苗。
- 采用网状Meta分析,血清阳转对比鼠脑灭活疫苗,不良事件和严重不良事件对比安慰剂。
主要发现
- 所有新型疫苗类别免疫原性均更好,Vero细胞灭活疫苗OR=2.98(95%CI:1.02-8.65),活嵌合疫苗OR=5.93(95%CI:1.73-20.32),差异有统计学意义。
- 鼠脑灭活疫苗不良事件比值比最高(OR=2.27;95%CI:1.59-3.23),新型疫苗不良事件风险与安慰剂无差异。
- 各类疫苗严重不良事件无差异。
关键数值与推荐
- 血清阳转:Vero细胞灭活疫苗对比鼠脑灭活疫苗OR=2.98(95%CI:1.02-8.65)。
- 血清阳转:活嵌合疫苗对比鼠脑灭活疫苗OR=5.93(95%CI:1.73-20.32)。
- 不良事件:鼠脑灭活疫苗对比安慰剂OR=2.27(95%CI:1.59-3.23)。
临床怎么用
- 选择乙脑疫苗时可优先考虑免疫原性更强且安全性相当的新型疫苗类别。
- 鼠脑灭活疫苗不良事件风险较高,接种决策时需权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Annually more than 100,000 Japanese encephalitis (JE) cases and 25,000 deaths worldwide are caused by JE virus infection. More than 15 JE vaccines are currently in use worldwide. It is unknown whether any of the vaccines is superior to the others in terms of immunogenicity and safety. METHODS: Four databases were systematically searched for randomised controlled trials that compared two or more types of JE vaccines. Vaccines were classified into four classes: inactivated mouse brain-derived (oldest class), inactivated Vero cell, live chimeric, and live attenuated. Network meta-analysis was used to generate mixed effect estimates against inactivated mouse brain-derived vaccines for seroconversion, and against placebo for adverse event (AE) and severe adverse event (SAE). RESULTS: 23 studies (38,496 participants) were included. All newer vaccine classes had better immunogenicity, the difference was statistically significant for inactivated Vero cell (OR = 2.98; 95 %CI: 1.02-8.65) and live chimeric (OR = 5.93; 95 %CI: 1.73-20.32) vaccines. Inactivated mouse-derived vaccines had the highest odds for AEs (OR = 2.27; 95 %CI: 1.59-3.23), the odds of AE of newer vaccines was not different to placebo. There was no difference in SAEs across vaccine classes. CONCLUSIONS: All newer JE vaccines have comparable safety profiles, live chimeric and inactivated Vero cell vaccines are the most immunogenic among the newer vaccine classes.
引用
- Furuya-Kanamori L, Xu C, Doi SAR, et al. Comparison of immunogenicity and safety of licensed Japanese encephalitis vaccines: A systematic review and network meta-analysis. Vaccine. 2021. PMID: 34175128. doi:10.1016/j.vaccine.2021.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。